The non-invasive prenatal testing (NIPT) market is encountering dynamic movements driven by progressions in genetic technologies. NIPT has acquired noticeable quality as a more secure option in contrast to conventional invasive prenatal systems, for example, amniocentesis and chorionic villus examining.
The pattern of deferred childbearing is a huge variable impacting the NIPT market. As additional women pick pregnancy at a more established age, the interest for non-invasive prenatal testing to survey fetal chromosomal abnormalities, like Down syndrome, has risen.
Expanded awareness among eager parents about the advantages of NIPT plays had an essential impact in market extension. The non-invasiveness of the technique, combined with its high awareness, has gathered acknowledgment and trust among pregnant women and medical services experts.
The extent of NIPT has extended past chromosomal abnormalities to incorporate the location of microdeletions and single-quality disorders. This expanding application range has broadened the market's scope, drawing in a bigger patient pool looking for thorough genetic data about their unborn child.
Coordinated efforts between symptomatic organizations and medical services suppliers have turned into a typical pattern, working with the combination of NIPT into routine prenatal consideration. Such organizations intend to smooth out testing processes and further develop accessibility for pregnant women.
The accessibility of protection inclusion for NIPT and endeavors to make these tests more reasonable are key elements affecting market elements. Accessibility and cost contemplations influence the dynamic interaction for both medical care suppliers and patients.
The Non-Invasive Prenatal Testing Market is expected to reach USD 11.3 Billion by 2030 at 13.1% CAGR during the forecast period 2022-2030.
Worldwide demand for NIPT is rising due to several factors, including a rise in doctors' preferences for sophisticated genetic screening for high-risk pregnancies, an eagerness to put off having children, and a boom in pregnancy-related problems in the last or second trimester. The devastating effect of COVID-19 has been unexpected and catastrophic worldwide, and NIPT has not seen any change regarding demand across all regions due to the pandemic. When the pandemic is finished, this market's demand and growth will resume to pre-pandemic levels, which will explain the increase in CAGR. A child's chance of developing genetic defects increases when genes and chromosomes mutate. According to reports, trisomy 21 is one of the most prevalent chromosomal disorders, affecting about 5,000 newborns annually in the United States.
The demand for an efficient screening tool for prenatal tests has increased due to the rising prevalence of chromosomal defects. Amniocentesis and chorionic villus sampling are invasive prenatal testing methods that might result in complications like miscarriage. As a result, there is a significant need for more effective, non-invasive, and safe tests and a fall in using these procedures. NIPT can be used to detect common trisomies in the fetus, such as Down syndrome, fetal rhesus D status, Turner syndrome, and sex chromosomal problems, as well as to determine the fetal sex. This is done using cell-free fetal DNA (cffDNA), which circulates in the mother's blood. Significant technological developments are being made in the sector to enhance testing capabilities. Many well-known companies and fresh start-ups seek financing for NIPT technique development and clinical testing. Government and business organizations are searching for research facilities and start-ups to provide cutting-edge testing methods to identify important genetic abnormalities through NIPT. Many nations have adopted rules that make non-invasive prenatal diagnostics the norm for prenatal screening rather than invasive examinations.
NIPT is the testing procedure done during the pregnancy period to monitor the fetal growth and related diagnosis. Annually it is predicted that around 21 million girls aged 15 to 19 years give birth in developing regions around the globe.
Thus, it is among the reasons why NIPT is needed for safe delivery of the baby.
The birth rate is expected to increase during the forecast period.
Market Influencer
Rising cases of premature pregnancy in developing and underdeveloped countries.
The Non-Invasive Prenatal Testing (NIPT) Market based on product type is broadly segmented into devices, consumables, and others.
The non-Invasive prenatal testing (NIPT) market based on technique is segmented into biochemical screening tests and ultrasound detection.
November 2023
Natera, Inc. announces that it has received FDA approval for its Panorama NIPT test to detect Down syndrome, trisomy 18, and trisomy 13 in pregnancies as early as 9 weeks of gestation. This is the earliest gestational age at which any NIPT test has been approved by the FDA.
Sequenom Laboratories announces that it has launched its new MaterniT21 PLUS test, an NIPT test that can detect Down syndrome, trisomy 18, and trisomy 13, as well as several other genetic disorders, in pregnancies as early as 10 weeks of gestation. The MaterniT21 PLUS test is the first NIPT test to be able to detect a wider range of genetic disorders.
Ariosa Diagnostics, Inc. announces that it has partnered with Illumina, Inc. to develop a new NIPT test that can be used to detect a wider range of genetic disorders, including single gene disorders. The partnership will combine Ariosa's expertise in NIPT with Illumina's expertise in sequencing technology to develop a new test that is more accurate and comprehensive than current NIPT tests.
Non-Invasive Prenatal Testing (NIPT) Market By Region
Non-Invasive Prenatal Testing (NIPT) Market Key Players
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)